Loading...
•
Mar 31, 2025
BioCryst Q1 2025 Earnings Report
Estimated Revenue:$130M
+53.0% YoY
Estimated EPS:-$0.0504
+78.5% YoY
Key Takeaways
BioCryst delivered strong Q1 2025 results with $145.5 million in revenue driven by significant growth in ORLADEYO sales, leading to a return to profitability and improved full-year guidance.
ORLADEYO revenue reached $134.2 million, up from $88.9 million a year ago.
Net income was $32,000, compared to a loss of $35.4 million in Q1 2024.
Operating income turned positive at $21.2 million.
Raised full-year ORLADEYO revenue guidance to $580M–$600M and expects profitability in 2025.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
BioCryst raised its full-year ORLADEYO revenue guidance and now expects to achieve profitability and positive cash flow by year-end 2025.
Positive Outlook
- Increased full-year ORLADEYO revenue guidance to $580M–$600M.
- Expects to achieve profitability in 2025, one year earlier than forecasted.
- Anticipates positive cash flow for full year 2025.
- Debt repayment of $75M will save ~$23.5M in interest.
- Clinical advancements in pipeline programs including Netherton syndrome and DME.
Challenges Ahead
- Increased full-year operating expense forecast to $440M–$450M.
- Cash balance declined from previous quarter.
- Stock-based compensation remains a non-GAAP adjustment burden.
- Still reliant on ORLADEYO for majority of revenue.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...